Cost minimization model for treatment of minor bleeding episodes in inhibitor patients - Methodological issues [2]

Haemophilia

Volumn 12, Issue 1, 2006, Pages 108-109

  Seremetis, S ^a   Joshi, Ashish V ^b   Asmussen, M ^a  

^a NOVO NORDISK A S   (Denmark)

^b NOVO NORDISK INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ANTIBODY TITER; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; DOSE CALCULATION; DRUG COST; DRUG EFFICACY; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HOME CARE; HUMAN; LETTER; LONG TERM CARE; PRIORITY JOURNAL; QUALITY OF LIFE;

DRUG ADMINISTRATION SCHEDULE; FACTOR VII; HEALTH CARE COSTS; HEMARTHROSIS; HEMOPHILIA A; HUMANS; MODELS, ECONOMIC; RECOMBINANT PROTEINS;

EID: 33645989171     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2006.01163.x     Document Type: Letter

References (4)

1. Putnam KG, Bohn RL, Ewenstein BM, Winkelmayer WC, Avorn J. A cost minimization model for the treatment of minor bleeding episodes in patients with haemophilia A and high-titre inhibitors. Haemophilia 2005; 11: 261-9.
2. Knight C, Paisley S, Wight J, Jones ML. Economic modelling of different treatment strategies for haemophilia A with high-responding inhibitors. Haemophilia 2003; 9: 521-40.
3. Odeyami AO, Guest JF. Modelling the economic impact of recombinant activated factor VII compared to activated prothrombin-complex concentrate in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. J Med Econ 2002; 5: 119-33.
4. Parameswaran R, Shapiro AD, Gill JC, Kessler CM. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia 2005; 11: 100-6.